What is sermorelin?
Sermorelin is a 29-amino-acid synthetic analogue of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that signals the anterior pituitary gland to secrete growth hormone (GH). Unlike exogenous GH injections, sermorelin works upstream: it prompts the pituitary to release GH in the pulsatile bursts that characterize physiologically normal GH secretion.
That pulsatility matters. Continuous, non-pulsatile GH elevation (as seen with exogenous GH) does not replicate what a healthy hypothalamic-pituitary axis produces. Sermorelin, when it works, preserves the pulsatile pattern, which keeps feedback loops intact and preserves the pituitary’s own secretory function.
Sermorelin was previously marketed in the United States as the FDA-approved injection product Geref (sermorelin acetate). That product is no longer commercially available, but sermorelin remains on the list of peptides that licensed 503A compounding pharmacies may prepare with a valid prescription from a licensed clinician.
How does intranasal peptide delivery work?
The nasal mucosa is a highly vascularized membrane. Drugs absorbed through it bypass first-pass hepatic metabolism, which can be an advantage over oral administration for peptides that are destroyed by digestive enzymes. That is why intranasal routes have attracted research interest for certain peptide compounds.
However, intranasal peptide bioavailability faces several challenges that do not apply to subcutaneous injection:
- Mucosal enzyme degradation: The nasal mucosa contains proteases and peptidases that can break down peptide molecules before they are absorbed.
- Mucociliary clearance: The nose constantly clears particles and substances toward the throat via ciliary movement. This limits the contact time between the peptide solution and the absorptive epithelium.
- Molecular weight limits: Larger peptides pass through nasal epithelium less efficiently than small molecules. Sermorelin at 29 amino acids sits in a range where intranasal absorption is possible but generally less efficient than subcutaneous delivery.
- Formulation dependence: Bioavailability is highly dependent on the specific formulation, including excipients, pH, and whether absorption enhancers are included. Not all intranasal peptide preparations behave the same way.
The subcutaneous injection route delivers the peptide directly into subcutaneous tissue, where it is absorbed into systemic circulation with predictable pharmacokinetics. The clinical literature on sermorelin, such as it exists, is built on the subcutaneous injection route.
Nasal delivery trades a lower, more variable per-dose uptake for a needle-free routine — a real adherence question, not just a chemistry one.
Why some clinicians offer nasal spray formulations
Patient adherence is a real clinical variable. Some people who would benefit from a growth hormone peptide protocol are needle-averse and will not consistently use a subcutaneous injection even if it is the more efficient route. In those cases, a clinician might consider an intranasal formulation as a trade-off: lower bioavailability per dose, but higher real-world compliance.
Dose can often be adjusted upward to partially compensate for lower bioavailability, though this is a clinical judgment rather than a straightforward calculation. It requires a clinician who understands the pharmacokinetic tradeoffs and can monitor response over time.
Additionally, some compounding pharmacies have developed sermorelin nasal spray formulations with absorption-enhancing excipients designed to improve mucosal uptake. The clinical evidence base for specific compounded intranasal sermorelin formulations is not robust, but the biochemical rationale for the approach is sound.
How does sermorelin nasal spray compare to subcutaneous injection?
Here is how the two administration routes compare across clinically relevant dimensions:
| Factor | Subcutaneous injection | Nasal spray |
|---|---|---|
| Bioavailability | High, predictable | Variable, generally lower |
| Onset / absorption | Consistent; well-characterized | Variable; formulation-dependent |
| Patient experience | Requires needle; small-gauge insulin type | Needle-free; preferred by needle-averse patients |
| Dosing | Clinician-set per established data | May require higher dose to compensate; clinician-set |
| Evidence base | Established; underpins all published protocols | Limited published clinical data |
| Tolerance | Headache, flushing possible in some patients | Same systemic effects; may add local nasal irritation |
How do you legally obtain sermorelin nasal spray?
Sermorelin nasal spray is a compounded prescription medication. To obtain it legally in the United States:
- A licensed clinician (physician or nurse practitioner) evaluates your health history, symptoms, and goals.
- The clinician determines whether sermorelin is appropriate and, if so, which formulation and dose fits your situation.
- A prescription is sent to a licensed 503A compounding pharmacy in the US.
- The pharmacy compounds the nasal spray and ships it directly to the patient.
There is no legal pathway to obtain prescription sermorelin without a clinician’s prescription. Products sold online without this pathway are not pharmaceutical-grade and are not subject to the quality controls that licensed pharmacies must meet. PepScribe partners exclusively with licensed 503A pharmacies that compound in the USA—no hidden overseas supply chain.
Frequently asked questions
What is sermorelin nasal spray?
Sermorelin nasal spray is a compounded intranasal formulation of sermorelin, a growth hormone-releasing hormone (GHRH) analogue. It is prepared by licensed 503A compounding pharmacies and requires a prescription from a licensed clinician.
Is sermorelin nasal spray as effective as injections?
The subcutaneous injection route has the most clinical data behind it and delivers the peptide directly into systemic circulation. Nasal bioavailability for peptides is generally lower than subcutaneous injection due to mucosal absorption barriers and enzymatic degradation. A prescribing clinician can review whether intranasal delivery is appropriate for your goals.
Does sermorelin nasal spray require a prescription?
Yes. Sermorelin is a prescription peptide regardless of formulation or route of administration. A licensed clinician must evaluate you and write a prescription before a compounding pharmacy can prepare and dispense the nasal spray.
Is sermorelin nasal spray FDA-approved?
No compounded sermorelin formulation is FDA-approved. Sermorelin acetate was previously marketed as an FDA-approved injection (Geref), but that product is no longer commercially available. Compounded sermorelin, including nasal spray, is prepared by 503A pharmacies under applicable compounding law.
Who is a candidate for sermorelin nasal spray?
That is a question for a licensed clinician, who will evaluate your growth hormone axis, symptom picture, and treatment goals. People who are needle-averse sometimes ask about intranasal routes, but clinician guidance on formulation choice is important.
What is sermorelin used for?
Sermorelin is a GHRH analogue that stimulates the pituitary to release growth hormone in a pulsatile, physiologically normal pattern. Clinicians prescribe it in the context of growth hormone optimization programs focused on body composition, sleep quality, and recovery support.